We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

A Clinical Trial of Oral Versus IV Iron in Patients With Chronic Kidney Disease

This study has been terminated.
(Terminated by the DSMB based on low chance of finding differences in mGFR slopes, but higher risk of serious adverse events in the IV iron group (aIRR = 1.60))
ClinicalTrials.gov Identifier:
First Posted: January 27, 2009
Last Update Posted: July 21, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Information provided by (Responsible Party):
Indiana University
January 26, 2009
January 27, 2009
April 28, 2016
July 21, 2016
July 21, 2016
August 2008
November 2014   (Final data collection date for primary outcome measure)
Mean Rate of Decline in mGFR in the Two Groups - Oral and IV Iron [ Time Frame: Baseline, 2 years ]
Plasma clearance of iothalamate was measured by administering an IV bolus of 5 mL of iothalamate meglumine and sampling 2 mL of blood at 0, 5, 10, 20, 30, 45, 60, 90, 120, 150, 180, 240, and 300 min after injection. Iothalamate was measured by high-performance liquid chromatography. Plasma clearance was calculated using a two-pool model using validated pharmacokinetic software. The mean modeled iothalamate mGFR slope (e.g., change from baseline to 2 years) in each group (IV iron vs. oral iron) was then calculated after adjustment for baseline log urinary protein/creatinine ratio.
Mear rate of decline in GFR in the two groups - oral and IV iron [ Time Frame: 2 years ]
Complete list of historical versions of study NCT00830037 on ClinicalTrials.gov Archive Site
Proteinuria [ Time Frame: Baseline, 2 years ]
Proteinuria was estimated using measurements of urinary protein and creatinine before iron administration at baseline and at periodic intervals thereafter. Mean change from baseline log urinary protein/creatinine ratio (g/g) is reported at 2 years.
Proteinuria [ Time Frame: 2 years ]
Not Provided
Not Provided
A Clinical Trial of Oral Versus IV Iron in Patients With Chronic Kidney Disease
Pathobiology of Kidney Disease: Role of Iron
The long-term goal is to assess the fall in kidney function measured by glomerular filtration rate (GFR) when patients with chronic kidney disease (CKD) are exposed to intravenous iron (IVIR). We hypothesize that in subjects with mild to moderate CKD, infusion of intravenous iron (IVIR), will generate oxidative stress and cause an inflammatory response that will be associated with a more rapid decline in glomerular filtration rate (GFR) compared to oral iron.
Intravenous iron is commonly utilized and is likely a mechanism of renal injury in patients with CKD. This proposal will provide translational data on the role of intravenous iron to progression of kidney disease in patients with CKD. Comparison of IV iron with oral iron will allow testing the hypothesis that IVIR will generate an inflammatory response and albuminuria in the short-term, that will directly lead to a greater rate of fall in GFR, in the long-term, compared to oral iron. We hypothesize that after administration of one gram of IV iron over a course of 8 weeks, renal injury as documented by albuminuria (and fall in GFR) will be increased with IV iron sucrose therapy compared to those randomized to oral iron therapy. A randomized, parallel group, controlled trial will be performed. GFR will be measures every 6 months for two years in 200 participants by iothalamate clearances.
Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Chronic Kidney Disease
  • Iron-deficiency Anemia
  • Drug: IV Iron
    IV iron sucrose 200 mg over 2 hours baseline visit, week 2, week 4, week 6 and week 8 for a total of 1000mg total dose. Further cycles of iv iron may be used based on periodic monitoring of iron stores.
    Other Name: Venofer
  • Drug: Ferrous Sulfate
    Oral ferrous sulfate 325mg three times daily over 8 weeks. Further cycles of oral iron may be used based on periodic monitoring of iron stores.
  • Experimental: IV Iron
    Intervention: Drug: IV Iron
  • Active Comparator: Oral Iron
    Intervention: Drug: Ferrous Sulfate
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Not Provided
November 2014   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Age greater than 18 years
  • Calculated GFR by MDRD formula < or = 60ml/min/1.73m2. We will use the MDRD formula that incorporates serum creatinine, age, race and sex, but not albumin, and blood urea nitrogen.
  • Presence of anemia and iron deficiency. Anemia will be defined as blood hemoglobin concentration <12g/dL and iron deficiency will be defined using National Kidney Foundation/Kidney Disease Outcome Quality Initiative (NFK-K/DOQI) Guidelines as serum ferritin concentration of <100ng/mL or serum transferrin saturation of <25%.

Exclusion Criteria:

  • Pregnant or breastfeeding women or women who are planning to become pregnant or those not using a reliable form of contraception (oral contraceptives, condoms, and diaphragms will be considered reliable).
  • Known hypersensitivity to iron sucrose (Venofer), iothalamate meglumine (Conray 60, Mallinckrodt) or iodine.
  • Anemia that requires RBD transfusion (Hgb <8g/dL) or may potentially need transfusion (active gastrointestinal bleeding). It would be unsafe to withdraw 150 mL blood over the study in such anemic patients.
  • Presence of acute renal failure defined as an increase in the baseline serum creatinine concentration of 0.5 mg/dl over 48 hours. This would produce oxidative stress by itself, may give unreliable rate of decline in renal function and may confound results.
  • History of IVIR use within 1 month of the study (may confound results of the study if the baseline oxidative stress is increased).
  • Evidence of iron overload (serum ferritin >800ng/nl or transferrin saturation >50%)
  • Anemia not caused by iron deficiency eg. sickle cell anemia.
  • Surgery or systemic or urinary tract infection within 1 month.
  • Organ transplant recipient or therapy with immunosuppressive agents. Nasal or inhaled corticosteroids will be permitted.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
U01DK071633 ( U.S. NIH Grant/Contract )
5U01DK071633-02 ( U.S. NIH Grant/Contract )
Not Provided
Not Provided
Indiana University
Indiana University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Principal Investigator: Rajiv Agarwal, MD FASN FAHA Indiana University
Indiana University
June 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP